177 related articles for article (PubMed ID: 29518148)
1. Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
Koda T; Namba A; Nakatsuji Y; Niino M; Miyazaki Y; Sugimoto T; Kinoshita M; Takata K; Yamashita K; Shimizu M; Fukazawa T; Kumanogoh A; Mochizuki H; Okuno T
PLoS One; 2018; 13(3):e0193986. PubMed ID: 29518148
[TBL] [Abstract][Full Text] [Related]
2. Sema4A inhibits the therapeutic effect of IFN-β in EAE.
Koda T; Okuno T; Takata K; Honorat JA; Kinoshita M; Tada S; Moriya M; Sakoda S; Mochizuki H; Kumanogoh A; Nakatsuji Y
J Neuroimmunol; 2014 Mar; 268(1-2):43-9. PubMed ID: 24439904
[TBL] [Abstract][Full Text] [Related]
3. Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase.
Koda T; Namba A; Kinoshita M; Nakatsuji Y; Sugimoto T; Sakakibara K; Tada S; Shimizu M; Yamashita K; Takata K; Ishikura T; Murata S; Beppu S; Kumanogoh A; Mochizuki H; Okuno T
J Neuroinflammation; 2020 Mar; 17(1):82. PubMed ID: 32169103
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Mallada-Frechin J; Meca-Lallana V; Barrero F; Martinez-Gines ML; Marzo-Sola ME; Ricart J; Garcia E; En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN
Rev Neurol; 2018 Sep; 67(5):157-167. PubMed ID: 30047118
[TBL] [Abstract][Full Text] [Related]
5. [Sema4A as a biomarker predicting responsiveness to IFN β treatment].
Nakatsuji Y
Rinsho Shinkeigaku; 2014; 54(12):972-4. PubMed ID: 25519959
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of fingolimod in a Portuguese real-world population.
Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
[TBL] [Abstract][Full Text] [Related]
9. Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis.
Nakatsuji Y; Okuno T; Moriya M; Sugimoto T; Kinoshita M; Takamatsu H; Nojima S; Kimura T; Kang S; Ito D; Nakagawa Y; Toyofuku T; Takata K; Nakano M; Kubo M; Suzuki S; Matsui-Hasumi A; Uto-Konomi A; Ogata A; Mochizuki H; Sakoda S; Kumanogoh A
J Immunol; 2012 May; 188(10):4858-65. PubMed ID: 22491253
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
Braune S; Lang M; Bergmann A;
J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389
[TBL] [Abstract][Full Text] [Related]
12. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
Walczak A; Kurkowska-Jastrzebska I; Zakrzewska-Pniewska B; Dorobek M; Brola W; Zajdel R; Bartosik-Psujek H; Stasiolek M; Kulakowska A; Rusek S; Tutaj A; Glabinski A; Wlodek A; Kochanowski J; Ciach A; Siger M; Kurowska K; Wicha W; Nojszewska M; Podlecka-Pietowska A; Czajka A; Kapica-Topczewska K; Bielecki B; Maciagowska-Terela M; Stepien A
Clin Neurol Neurosurg; 2019 Sep; 184():105453. PubMed ID: 31376776
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
[TBL] [Abstract][Full Text] [Related]
16. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
Haas J; Jeffery D; Silva D; Meier DP; Meinert R; Cohen J; Hartung HP
Mult Scler Relat Disord; 2019 Nov; 36():101335. PubMed ID: 31557679
[TBL] [Abstract][Full Text] [Related]
17. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
[TBL] [Abstract][Full Text] [Related]
19. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal real-life comparison study of natalizumab and fingolimod.
Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]